Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
47.61
-0.16 (-0.33%)
At close: Dec 18, 2025, 4:00 PM EST
47.97
+0.36 (0.76%)
Pre-market: Dec 19, 2025, 7:47 AM EST
Novo Nordisk Revenue
Novo Nordisk had revenue of 74.98B DKK in the quarter ending September 30, 2025, with 5.14% growth. This brings the company's revenue in the last twelve months to 315.60B, up 16.64% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
315.60B DKK
Revenue Growth
+16.64%
P/S Ratio
4.28
Revenue / Employee
4,080,247 DKK
Employees
77,349
Market Cap
212.43B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | 122.02B | 10.19B | 9.11% |
| Dec 31, 2018 | 111.83B | 135.00M | 0.12% |
| Dec 31, 2017 | 111.70B | -84.00M | -0.08% |
| Dec 31, 2016 | 111.78B | 3.85B | 3.57% |
| Dec 31, 2015 | 107.93B | 19.12B | 21.53% |
| Dec 31, 2014 | 88.81B | 5.23B | 6.26% |
| Dec 31, 2013 | 83.57B | 5.55B | 7.11% |
| Dec 31, 2012 | 78.03B | 11.68B | 17.60% |
| Dec 31, 2011 | 66.35B | 5.57B | 9.16% |
| Dec 31, 2010 | 60.78B | 9.70B | 18.99% |
| Dec 31, 2009 | 51.08B | 5.53B | 12.13% |
| Dec 31, 2008 | 45.55B | 3.72B | 8.90% |
| Dec 31, 2007 | 41.83B | 3.09B | 7.97% |
| Dec 31, 2006 | 38.74B | 4.98B | 14.76% |
| Dec 31, 2005 | 33.76B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Abbott Laboratories | 43.84B |
NVO News
- 22 hours ago - Wegovy Maker Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema - WSJ
- 2 days ago - Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly - CNBC
- 3 days ago - Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars - Benzinga
- 6 days ago - EU drugs regulator backs higher dose of Novo's Wegovy - Reuters
- 6 days ago - Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss - GlobeNewsWire
- 7 days ago - Novo Nordisk Launches $24 a Week Ozempic in This Country. Why the Big Price Cut. - Barrons
- 7 days ago - Novo Nordisk brings Ozempic to India as weight-loss demand accelerates - Invezz
- 7 days ago - Novo Nordisk launches blockbuster diabetes drug Ozempic in India - Reuters